A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2002
10/01/2002	US6458590 Methods and compositions for treatment of restenosis
10/01/2002	US6458586 Replication of defective vectors with mutations and deletions; gene therapy, vaccines, genetic engineering
10/01/2002	US6458585 Cytokine-free culture of dendritic cells
10/01/2002	US6458579 For use in investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency
10/01/2002	US6458575 Useful in the diagnosis, prevention, and treatment of cancer, autoimmune/inflammatory disorders, and reproductive disorders; screening libraries of peptides and antibodies; purification; amino acid sequences
10/01/2002	US6458574 Highly purified alpha-galactose a glycoforms by charge alterations by increasing the sialic acid content and/or by increasing the phosphorylation; half-life; bioavailability; fabry's disease; cardiovascular disorders
10/01/2002	US6458572 Phosphatidylglycerophosphate synthase from Staphylococcus aureus
10/01/2002	US6458571 Excitatory amino acid transporter 3, EAAT3, polypeptides
10/01/2002	US6458567 Hepatitis C Virus ribozymes
10/01/2002	US6458564 Amino acid sequence of the protease; for treating imbalance of desquamation
10/01/2002	US6458563 Dna which encodes protein of defined amino acid sequence; stable, less immunogenic treatment of hemophilia
10/01/2002	US6458561 Human NIM1 kinase
10/01/2002	US6458551 Estrogen receptor
10/01/2002	US6458541 Predicting likelihood of diagnosis by determining polymorphism in brain derived neurotrophic factor where presence of adenine at position 404 instead of guanine indicates lower likelihood
10/01/2002	US6458529 Assays for promoter operability in central nervous system cells
10/01/2002	US6458527 Using synthetic or recombinant polypeptides as gag antigen; diagnosis of human immunodeficiency virus
10/01/2002	US6458386 Medicaments based on polymers composed of methacrylamide-modified gelatin
10/01/2002	US6458383 Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
10/01/2002	US6458375 Containing hydrogel of high molecular weight mucopolysaccharide
10/01/2002	US6458366 Compounds and methods for diagnosis of tuberculosis
10/01/2002	US6458365 Method for treating headache
10/01/2002	US6458364 Non-splicing variants of gp350/220
10/01/2002	US6458360 Soluble complement regulatory molecules
10/01/2002	US6458359 Chimeric gene formed by the dna sequences that encode the antigenic determinants of four proteins of l. infantum and protein encoded by said gene, and pharmacuetical composition useful for preventing and/or treating leishmaniosis in animals or humans
10/01/2002	US6458357 Retro-inverso neurotrophic and analgesic peptides
10/01/2002	US6458356 Antibody-induced apoptosis
10/01/2002	US6458354 Molecular complexes which modify immune responses
10/01/2002	US6458351 Yeast extracts
10/01/2002	US6458350 ULBP DNA and polypeptides
10/01/2002	US6458349 For treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, psoriasis; for wound healing
10/01/2002	US6458147 Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
10/01/2002	US6458026 Transfection complex comprising a first component comprising one or more lipids, a second component comprising an oligolysine linked via a peptide bond to an integrin-binding peptide, and a third component comprising a nucleic acid
10/01/2002	CA2404919A1 Diagnostic and therapeutic agents for rheumatoid arthritis
10/01/2002	CA2281895C Ikb kinases
10/01/2002	CA2255826C Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same
10/01/2002	CA2248047C Antagonism of endothelin actions
10/01/2002	CA2220461C Therapeutic compounds comprised of anti-fc receptor antibodies
10/01/2002	CA2210258C Substituted oxazolidine calpain and/or cathepsin b inhibitors
10/01/2002	CA2168113C Therapeutic peptide derivatives
10/01/2002	CA2145411C Viscous liquid xylitol compositions and process for preparing the same
10/01/2002	CA2124284C Drug for neuroprotection
10/01/2002	CA2119930C Production of chimeric antibodies - a combinatorial approach
10/01/2002	CA2103546C Modified factor vii
10/01/2002	CA2077670C Method for enhancing antibody transport through capillary barriers
10/01/2002	CA2075358C Multimers of the soluble forms of tnf receptors, their preparation and pharmaceutical compositions containing them
10/01/2002	CA2073031C Anti-cd4 antibody homologs useful in prophylaxis and treatment of aids, arc and hiv infection
10/01/2002	CA2071520C Elimination of activated lymphocytes
10/01/2002	CA1341391C Protective peptides derived from human immunodeficiency virus-1 gp160
09/2002
09/28/2002	CA2340455A1 Nucleic acids and proteins of the mycoplasma hyopneumoniae mhp3 gene and uses thereof
09/26/2002	WO2002075278A2 Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
09/26/2002	WO2002074996A1 Gene regulation
09/26/2002	WO2002074981A2 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
09/26/2002	WO2002074980A2 Muteins of hypoxia inducible factor alpha and methods of use thereof
09/26/2002	WO2002074963A1 Dengue viruses that are replication defective in mosquitos for use as vaccines
09/26/2002	WO2002074959A2 Human leucine-rich repeat containing protein expressed predominately in nervous system tissues, hlrrns1
09/26/2002	WO2002074957A2 Stress-responsive activator of p300 (strap) protein
09/26/2002	WO2002074956A2 Dopaminergic neuronal survival-promoting factors and uses thereof
09/26/2002	WO2002074955A2 Oligonucleotides for regulating the gene coding for tnf$g(a) and/or genes controlled thereby and use thereof
09/26/2002	WO2002074945A1 Method for cleaving human growth hormone gh
09/26/2002	WO2002074943A2 Nucleic acid molecules coding for a dextran-saccharase catalysing the synthesis of dextran with alpha 1,2-osidic sidechains
09/26/2002	WO2002074939A1 Use of gram-negative bacterial membrane fraction for inducing the maturation of dendritic cells
09/26/2002	WO2002074931A2 Inhibitors and disassemblers of fibrillogenesis
09/26/2002	WO2002074919A2 Protein-protein interactions
09/26/2002	WO2002074913A2 Nucleic acid-associated proteins
09/26/2002	WO2002074907A2 Methods of modulating surfactant production
09/26/2002	WO2002074905A2 Leptin induced genes
09/26/2002	WO2002074810A2 Isolated human ion channel proteins, nucleic acid molecules encoding human ion channel proteins, and uses thereof
09/26/2002	WO2002074808A2 Modified insulin with reduced immunogenicity
09/26/2002	WO2002074807A2 Chimpanzee erythropoietin (chepo) - immunoadhesins
09/26/2002	WO2002074806A2 New interferon beta-like molecules
09/26/2002	WO2002074805A1 Soluble rage protein
09/26/2002	WO2002074803A2 Regulation of human icos v protein
09/26/2002	WO2002074798A2 The genome of a bifidobacterium
09/26/2002	WO2002074794A2 Compositions useful in gene therapy
09/26/2002	WO2002074792A1 Fo-6979 substances and process for producing the same
09/26/2002	WO2002074788A2 TRP2 ISOFORM TRP2-6b CONTAINING HLA-A2-RESTRICTED EPITOPES
09/26/2002	WO2002074786A2 Methods of modulating surfactant production
09/26/2002	WO2002074784A2 Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
09/26/2002	WO2002074783A2 Modified interferon beta with reduced immunogenicity
09/26/2002	WO2002074782A2 Isolation and purification procedure of vasopeptidase peptide inhibitors
09/26/2002	WO2002074777A2 Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity
09/26/2002	WO2002074761A1 Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors
09/26/2002	WO2002074719A2 Inhibitors of plasmepsins
09/26/2002	WO2002074337A1 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
09/26/2002	WO2002074331A2 Mutated mhc molecules for use in immune suppression
09/26/2002	WO2002074329A1 Pharmaceutical composition applied to the treatment of the peyronie disease and corresponding obtention process
09/26/2002	WO2002074328A1 Methods of treating respiratory conditions
09/26/2002	WO2002074327A2 Compositions and methods for treating gonadotrophin related illnesses
09/26/2002	WO2002074326A2 Urocortin-iii and uses thereof
09/26/2002	WO2002074324A1 Collagen-binding adhesin from staphylococcus epidermidis and method of use
09/26/2002	WO2002074323A2 Using neural thread proteins to treat tumors and other hyperproliferative disorders
09/26/2002	WO2002074322A2 Human growth hormone for treating children with abnormal short stature and kits and methods for diagnosing gs protein dysfunctions
09/26/2002	WO2002074316A1 Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
09/26/2002	WO2002074293A2 Methods for restoring cognitive function following systemic stress
09/26/2002	WO2002074289A2 Antitumor compositions containing taxane derivatives
09/26/2002	WO2002074250A2 Methods and reagents for decreasing clinical reaction to allergy
09/26/2002	WO2002074249A2 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
09/26/2002	WO2002074247A2 Pharmaceutical formulations for sustained release
09/26/2002	WO2002074243A2 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
09/26/2002	WO2002074239A2 Compositions and methods for the treatment and clinical remission of psoriasis

1 ... 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 ... 3163